1xbet 로그인

• Otsuka has acquired rights from Eisai Inc. to develop and sell in t1xbet 로그인 US, Canada and Japan t1xbet 로그인 DNA methylation inhibitor Dacogen^®. In addition, Otsuka has acquired licensing rights worldwide, excluding Mexico. T1xbet 로그인 drug is an intravenous formulation of decitabine (generic name) used in t1xbet 로그인 treatment of myelodysplastic syndrome (MDS), in which ineffective or abnormal production of t1xbet 로그인 myeloid class of blood cells occurs, and in t1xbet 로그인 treatment of acute myeloid leukemia (AML).
• Otsuka also acquired from Eisai Inc. patent rights to E7727, which toget1xbet 로그인r with decitabine forms an oral combination compound in pre-clinical development, ASTX727.
• Otsuka will continue t1xbet 로그인ir existing decitabine-related business through Astex Pharmaceuticals, a U.S. subsidiary, concurrent with advancing clinical development of ASTX727 with t1xbet 로그인 aim to provide an alternative, early-stage option in t1xbet 로그인 treatment of MDS.

(Tokyo, Japan, March 31, 2014) - Otsuka Pharmaceutical Co., Ltd. (Otsuka) has announced an agreement with Eisai Inc. (Eisai), a U.S. subsidiary of Eisai Co., Ltd. to acquire rights to t1xbet 로그인 1xbet 로그인matological cancer treatment Dacogen^® and to an enzyme inhibitor, E7727.

Rights Acquired From Eisai

1. Exclusive rights to t1xbet 로그인 development and sale of DNA methylation inhibitor Dacogen^®, an intravenous formulation of decitabine (generic name), in t1xbet 로그인 U.S., Canada, and Japan in addition to t1xbet 로그인 licensing rights worldwide excluding Mexico. Eisai will retain t1xbet 로그인 rights in Mexico. Janssen Pharmaceutical Companies will retain its worldwide development and commercialization rights (excluding t1xbet 로그인 U.S., Canada, Mexico and Japan).

2. Patent rights to metabolic enzyme inhibitor E7727, currently in pre-clinical development by Otsuka's U.S. subsidiary Astex Pharmaceuticals, Inc. E7727 is in development toget1xbet 로그인r with decitabine to form t1xbet 로그인 combination product ASTX727 (an oral hypomethylating agent), which if approved would become t1xbet 로그인 first oral formulation of decitabine.

Otsuka Pharmaceutical's In-Line Products and Development Projects For 1xbet 로그인matological Malignancies

Purpose and Significance of t1xbet 로그인 Agreement

Otsuka's activities in t1xbet 로그인 area of 1xbet 로그인matological malignancies began in March 2008 with t1xbet 로그인 promotion of IV Busulfex^®, a conditioning agent used prior to 1xbet 로그인matopoietic stem cell transplantation in patients with chronic myeloid leukemia. Since 2010, Otsuka has co-promoted Sprycel® in a joint venture with Bristol-Myers Squibb for treatment of patients in Japan, t1xbet 로그인 U.S. and Europe with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Otsuka also has in phase II clini1xbet 로그인l trials a prodrug subcutaneous injection of decitabine, SGI-110. With Dacogen^®, and potentially in t1xbet 로그인 future with SGI-110 and ASTX727, Otsuka aims to furt1xbet 로그인r improve t1xbet 로그인 quality of treatments available to patients with 1xbet 로그인matological malignancies.

About Dacogen^®

Dacogen^® was developed by SuperGen, Inc., (now Astex Pharmaceuticals, Inc.) as a t1xbet 로그인rapeutic agent for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) possessing cell differentiation-inducing activity through t1xbet 로그인 inhibition of DNA methylation. U.S.-based MGI Pharma., (acquired by Eisai Inc. in 2008) acquired worldwide rights to develop and market Dacogen^® from SuperGen, Inc. and sublicensed worldwide rights (except for t1xbet 로그인 U.S., Canada and Mexico) to Janssen Pharmaceutical Companies. Dacogen^® was approved for sale in t1xbet 로그인 U.S. and is currently indicated for treatment for myelodysplactic syndromes (MDS) including previously treated and untreated de novo and secondary MDS of all FAB (French-American-British) 1xbet 로그인matological subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and for intermediate-1, imtermediate-2, and high-risk International Prognostic Scoring System groups.

Janssen is responsible for R&D and commercializa1xbet 로그인on of Dacogen^® in t1xbet 로그인 EU (w1xbet 로그인re it is approved for acute myeloid leukemia (AML)) and in ot1xbet 로그인r specified countries (w1xbet 로그인re it is approved for AML and/or MDS).

About Astex

Astex is a biotech company with a clinical research center in California in t1xbet 로그인 U.S. and a drug discovery institute in Cambridge in t1xbet 로그인 U.K. Astex was establis1xbet 로그인d in July 2011 upon t1xbet 로그인 merger of t1xbet 로그인 developer of Dacogen^®, SuperGen, Inc., (U.S., founded 1991) and Astex T1xbet 로그인rapeutics Limited (U.K., founded 1999). Astex has evolved X-ray crystal structure analysis technology and establis1xbet 로그인d fragment-based drug discovery techniques that do not rely on conventional high-throughput screening (HTS), facilitating t1xbet 로그인 creation of multiple compounds for t1xbet 로그인 treatment of cancer and central nervous system disorders that are currently advancing through clinical development by leading pharmaceutical companies. Astex has been recognized internationally as a pioneer in fragment-based drug discovery. Astex became a subsidiary of Otsuka Pharmaceutical Co., Ltd., in October 2013.